Unpacking Pharma's Future: Costs, Generics, and the Tug-of-War for Access

Unlocking Affordable Medicine: A Call for Smarter Biosimilar Regulation

The Great Unbundling: Why Weight Loss Drug Prices Are Finally Coming Down

Ensuring Everyone Can Afford Medicine: A Call for Policy on Non-Scheduled Drugs

Pharma's Unfolding Drama: 340B Clashes, Vaccine Progress, and Cancer Innovation

The Fight for Affordable Medicine: Hospitals Take On 340B Program Changes

Unpacking the Trump Administration's Bold Move to Cut Drug Costs

Eli Lilly Slashes Zepbound Prices Amid Political Pressure and Trump's Claims

Medicare's Big Gamble: Are Pharmacies Truly Ready for Drug Price Negotiations?

The GLP-1 Gold Rush: Will Trump Rewrite the Rules for Eli Lilly and Novo Nordisk?

Navigating the Shifting Tides: A Look at Life Sciences in Q3 2025

The Astonishing Disparity: Why Miebo's Price Tag is a World Apart Across the Atlantic

A Brave New World of Medicine: Unpacking the Promise and Peril of Biotech Drugs

Cigna's Prescription for Change: Saying Goodbye to Drug Rebates

When States Take on Drug Prices: Connecticut's Bold Move and the Unfolding Legal Drama

The Shadow Returns: What Trump's Drug Pricing Encore Means for Your Medicine Cabinet

The Rx Revolution: How Startups Are Rewriting the Rules of Drug Affordability

Gilead Halts HIV Drug Price Hikes Amidst Growing Scrutiny and Public Pressure

The Pharmaceutical Frontier: How the FDA and White House Are Accelerating Cures and Revolutionizing Drug Prices

California's Landmark Initiative: State-Branded Insulin Set to Transform Diabetes Care and Affordability

The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs

Europe's Bold New Pharma Gambit: A High-Stakes Bet on Access Over Profit?

A Pivotal Moment: HHS Advances Major Drug Pricing Rule for Review

Pharma's Big Win: How a Judge's Ruling Ignited Big Pharma Stocks

Crucial Medicare Drug Price Loophole Fix Stalled: A Setback for Patient Savings

Trump's Bold Play: Delaying Pharma Tariffs for Deeper Drug Price Deals

The Pharmaceutical Tsunami: How a Second Trump Term Could Reshape Drug Pricing, Medicare, and Vaccines

Trump's Pfizer Deal: A 'Devastating' Blow to PBMs and Insurers, Warns LaMattina

A Pharmaceutical Powerhouse Pivots: Pfizer Embraces Trump's 'Most Favored Nation' Pricing

A Landmark Deal: Pfizer Slashes Drug Costs for Medicaid Patients in Trump Administration Agreement

The "TrumpRx" Initiative: A Disruptive Force in the Pharmaceutical Landscape, Challenging Giants Like Pfizer

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

Trump's Landmark Drug Price Promise: A Deadline Vanished, Unnoticed

Indian Pharma's Unwavering Allure: Why Mutual Funds Are Doubling Down Amidst Global Headwinds

America's Pharmaceutical Future: Rekindling the Spark of Innovation

A Breath of Relief: How Trump's Drug Tariffs Spare India's Generic Pharma Giants

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

Bristol Myers Squibb Shakes Up Psoriasis Market with Massive Discount for Sotyktu

The Dawn of a New Era: Keytruda's Patent Cliff and the Future of Cancer Care